Stockpolly
Search
VTVT · NASDAQ · Biotechnology

vTv Therapeutics (VTVT)

Develops oral small molecules for diabetes, centered on cadisegliatin alongside insulin.

$33.61
At close+1.66 (+5.20%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue0010000000370
Cost of revenue000000000000
Gross profit0010000000370
557775781181414
Research & development323332347499
334433444455
General & administrative334433444455
Other expenses000000000000
Operating income−5−5−6−7−7−5−7−8−11−823−14
−300110000111
Interest income000110000111
Interest expense000000000000
Other non-operating income300−1−10000−1−1−1
Income before tax−9−4−6−6−6−4−6−7−10−724−13
Income tax expense000000000000
Net income from continuing operations−9−4−6−6−6−4−6−7−10−724−13
Net income−7−3−5−5−5−4−5−6−9−724−13
EPS, basic−$3.27−$1.67−$1.17−$0.81−$0.88−$0.63−$0.77−$0.92−$1.08−$0.85$2.87−$1.05
EPS, diluted−$3.27−$1.67−$1.17−$0.81−$0.88−$0.63−$0.77−$0.92−$1.08−$0.85$2.87−$1.05
Weighted average shares, basic2246567788812
Weighted average shares, diluted2246567788812
EBITDA−9−4−6−6−6−4−6−7−10−724−13
Depreciation & amortization000000000000
EBIT−9−4−6−6−6−4−6−7−10−724−13